GlassScriptPhysician profile
James K Zelenak
NPI 1154397156
$14,824.47
in general payments reported to CMS, 2019-2025
73 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,572 · 2020: $1,657 · 2021: $1,764 · 2022: $1,690 · 2023: $1,977 · 2024: $2,708 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,140.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,798.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,640.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,400.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,233.59 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $1,051.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,024.34 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $641.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $572.19 | 2019-2025 | Trintellix |
| Abbott Laboratories | $503.39 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $440.09 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $400.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $308.48 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Gilead Sciences, INC. | $274.12 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $255.26 | 2019-2025 | Ajovy |
| Shield Therapeutics INC | $171.51 | 2023-2025 | Accrufer |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Zelenak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.